NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws.
On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. According to the article, "HilleVax's stock took a nosedive after the vaccine biotech's sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE)." The article continues, "The virus-like particle-based vaccine, dubbed HIL-214, missed all primary and secondary endpoints of the NEST-IN1 study of more than 2,800 infants aged about five months of age in the U.S. and Latin America." To obtain additional information, go to:
https://zlk.com/pslra-1/hillevax-inc-lawsuit-submission-form?prid=98990&wire=1
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP